Skip to main content
RFL
NYSE Life Sciences

Rafael Holdings Shareholders Approve 1 Million Share Increase for Equity Incentive Plan

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
7
Price
$1.259
Mkt Cap
$64.2M
52W Low
$1.12
52W High
$3.19
Market data snapshot near publication time

summarizeSummary

Rafael Holdings' shareholders approved an increase of 1,000,000 shares for its equity incentive plan, representing a notable potential dilution, alongside the routine election of directors and auditor ratification.


check_boxKey Events

  • Equity Incentive Plan Expanded

    Shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing the number of Class B common stock shares available for awards by 1,000,000. This represents a potential dilution of approximately $1.26 million based on the current stock price.

  • Directors Elected

    All six nominees for the Board of Directors, including Susan Y. Bernstein, Alan Grayson, Howard S. Jonas, Markus W. Sieger, Mark N. Stein, and Michael J. Weiss, were elected for one-year terms with strong shareholder support (84.73% to 86.70% 'Votes For').

  • Auditor Ratified

    The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending July 31, 2026, was ratified by shareholders with 99.13% 'Votes For'.


auto_awesomeAnalysis

Rafael Holdings' shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing the shares available for awards by 1,000,000. This represents a potential dilution of nearly 2% of the company's current market capitalization, which is a significant amount for a company of this size. While equity incentive plans are common for employee compensation and retention, this expansion creates an overhang and could impact existing shareholder value. The other items, including the election of directors and the ratification of the independent auditor, were routine matters passed with strong shareholder support.

At the time of this filing, RFL was trading at $1.26 on NYSE in the Life Sciences sector, with a market capitalization of approximately $64.2M. The 52-week trading range was $1.12 to $3.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed RFL - Latest Insights

RFL
Apr 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
RFL
Mar 16, 2026, 4:40 PM EDT
Filing Type: 10-Q
Importance Score:
7
RFL
Mar 16, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
RFL
Jan 12, 2026, 4:29 PM EST
Filing Type: 8-K
Importance Score:
7